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Should oral misoprostol be used to prevent postpartum haemorrhage in home 
birth settings in low resource countries? A systematic review of the evidence. 
 
 
Abstract 
 
Background: Using misoprostol to prevent postpartum haemorrhage (PPH) in home birth 
settings remains controversial. 
 
Objective: To review the safety and effectiveness of oral misoprostol in preventing PPH in home 
birth settings. 
 
Search Strategy: the Cochrane Library, PubMed, and POPLINE were searched for articles 
published until 31 March 2012. 
 
Selection criteria: Studies, conducted in low resource countries, comparing oral misoprostol to a 
placebo or no treatment in a home birth setting. Studies of misoprostol administered by other 
routes were excluded.  
 
Data collection and analysis: Data were extracted by two reviewers and independently checked 
for accuracy by a third. Quality of evidence was assessed using GRADE criteria. Data were 
sythesised and meta-analysis performed where appropriate. 
 
Main results: Ten papers describing two randomised and four non-randomised trials. 
Administration of misoprostol was associated with a significant reduction in the incidence of 
PPH (RR = 0.58, 95% CI: 0.38 to 0.87), additional uterotonics (RR = 0.34, 95% CI: 0.16 to 0.73) 
and referral for PPH (RR = 0.49, 95% CI: 0.37 to 0.66). None of the studies was large enough to 
detect a difference in maternal mortality and none reported neonatal mortality. Shivering and 
pyrexia were the most common side effects. 
 
Conclusions: The finding that distribution of oral misoprostol through frontline health workers is 
effective in reducing the incidence of PPH could be a significant step forward in reducing 
maternal deaths in low resource countries. However, given the limited number of high quality 
studies in this review, further randomised control trials are required to confirm the association, 
particularly in different implementation settings. Adverse effects have not been systematically 
captured, and there has been limited consideration of the potential for inappropriate or 
inadvertent use of misoprostol. Further evidence is needed to inform the development of 
implementation and safety guidelines on the routine availability of misoprostol. 
 
 
Keywords: misoprostol, postpartum haemorrhage, home birth settings, low resource countries. 
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Introduction 
Considerable debate surrounds the use of misoprostol to prevent postpartum haemorrhage 
(PPH) in home birth settings. PPH is traditionally defined as “blood loss greater than or equal to 
500 ml within 24 hours after birth”1. Haemorrhage remains the leading cause of maternal 
mortality in sub-Saharan Africa and South-east Asia2. Oxytocin is acknowledged as the drug of 
choice for the active management of the third stage of labour and is therefore recommended for 
the prevention of PPH within a facility setting3,4. However, there has been significant interest in 
the role that misoprostol might play in countries where a high proportion of births occur at home. 
For example, it is estimated that in rural areas of Bangladesh and Ethiopia more than 90% of 
women give birth at home5. In such circumstances the proportion of births attended by skilled 
health personnel is low; 18% of births in Bangladesh and 6% in Ethiopia5. Although the picture 
is improving, it is estimated that 130-180 million women (43-48%) in sub-Saharan Africa and 
South Asia will give birth without a skilled attendant in the next 5 years6. Misoprostol has 
attracted interest because it is inexpensive7, does not require cold chain storage8, and it has 
been suggested that it can be administered by a non-skilled attendant without additional 
equipment9. Supporters of community distribution argue that giving misoprostol to women in 
areas without skilled birth attendants will have a significant impact on the prevention of PPH10-12; 
with one simulation model, based on clinical data, suggesting as much as a 38% reduction in 
maternal deaths due to PPH13. Others, including the World Health Organization, have 
suggested that further evidence is required before distribution to non-skilled attendants and to 
women can be recommended14. Concerns include inappropriate use (where misoprostol is used 
for a reason other than PPH prevention) or incorrect use of the tablets (such as administration 
prior to the birth of the baby), adverse effects (that may include fever and/or chills, nausea and 
vomiting, diarrhea, and pain15), and the possibility that community distribution of misoprostol 
may distract from the message about the importance of facility birth16,17. Despite these 
concerns, there is evidence of widespread use of misoprostol, facilitated in part by government 
approval18,19, the addition of misoprostol to national essential medicine lists20,21 and more 
recently to the WHO Model List of Essential Medicines22. 
 
We sought to examine the evidence base on misoprostol as a potential add-on for a clean birth 
kit (CBK). CBKs vary considerably in name and content, but at a minimum these single-use, 
prevention kits should contain components to facilitate a clean surface for delivery (e.g. a plastic 
sheet), clean hands of the birth attendant (e.g. soap), and clean cutting of the umbilical cord 
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(e.g. razor blade)23. In an earlier review of the contents of CBKs we found that most kits 
included a plastic sheet, soap, a clean blade, and a clean cord tie or clamp24. Some kits had 
other components such as gloves and gauze swabs, but there was
 
no evidence of the inclusion 
of misoprostol within the kits. However, subsequent to this review a company has begun 
producing and distributing CBKs containing misoprostol tablets25 as part of a substantial 
programme to prevent PPH after home birth26. Given the interest in this area, we aimed to 
review the safety and effectiveness of oral misoprostol in reducing the incidence of PPH in 
home birth settingsa in low resource countries (LRCs). Previous reviews have examined 
misoprostol use, but have not specifically focused on home birth settings27. 
 
 
Methods 
 
Electronic databases were searched from the starting date of the database to 31 March 2012. 
Two independent searches were conducted; the first search was limited to randomised 
controlled trials, while the second search included all studies reporting effectiveness. The 
search strategy was expanded to account for limited findings in the first search, particularly with 
regard to secondary outcomes such as the use of additional uterotonics and referral. We did not 
limit the second search by study design to ensure as wide a search as possible. The search 
strategy took into account the participants (LRCs) and the intervention (oral misoprostol). An 
LRC was defined as any country in the World Bank income groups of “low income”, “lower 
middle income” and “upper middle income”28. We included only studies of oral misoprostol 
compared with a placebo or no treatment in a home birth setting. Administration of misoprostol 
via the oral route ensures a fast uptake, but a shorter duration of action than either the 
sublingual or buccal routes29. This would be appropriate if the medication is to be included 
within CBKs that may be used by women in the absence of a skilled birth attendant. We chose 
not to include sublingual administration as part of the intervention considered in this review, 
since this route has been associated with a higher rate of maternal fever than the oral route30 
and could require more training in administration. Outcomes were not specified terms in the 
search strategy to ensure as wide a search as possible. The Cochrane Library, PubMed, and 
POPLINE were searched. The search strategy was guided by a library science expert. Medical 
subject headings (MESH) included “Parturition”, and “Delivery, Obstetric”. Keywords were: 
“labour” or “labor, “”clean delivery”, “safe delivery”, “birth*”, “childbirth*”, “intrapartum”, 
                                                 
a
 In addition to the home, this includes home-like settings within the community (for example birth huts). It does 
not include facilities, either hospitals or health centers.  
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“peripartum”, “perinatal”, “postpartum”, “postnatal”, “obstetric*”, “misoprostol” and 
“haemorrhage” or “hemorrhage”. Additional studies were identified through reference lists of 
retrieved articles, recommendations sent to the researchers by experts in maternal and child 
health, and contact with authors of published articles. The search was limited to human subjects 
only. Just prior to submission of this paper a further systematic review was published31. This did 
not attempt to isolate the effectiveness of oral misoprostol for prevention PPH in home birth 
settings. Nor did it include the wider range of studies and outcomes included in this review.  
 
Titles and abstracts of identified studies were screened by three researchers (BA, CS, & VH). 
Studies were included if they were conducted in LRCs, in a home birth setting, and compared 
oral misoprostol use to placebo or no treatment. Studies evaluating the use of misoprostol 
administered by other routes, in facility settings, or for reasons other than the prevention of 
postpartum haemorrhage, were excluded (Figure 1); in some cases this could only be 
ascertained after full text review. Full text papers were reviewed and data extracted (by CS & 
VH). The extracted data was independently checked for accuracy and detail (by BA). Where a 
study was reported in more than one paper, all papers were reviewed to ensure that all the 
relevant data were extracted. Methodological quality of the studies was assessed and a simple 
quality score32 was applied to reflect the researchers’ confidence that the study analysis was 
assessing a causal association.  
 
The relative risk, with 95% confidence intervals, was calculated (by BA) where this was not 
provided by the authors. Meta-analysis was performed using Review Manager (RevMan) 
version 5 statistical software (by BA). Findings with reported zero events in their study arms 
were excluded from the analysis. The findings across interventions were synthesised using a 
random effects model, which takes into account the heterogeneity of the studies, to estimate the 
relative risk of postpartum haemorrhage, use of additional uterotonics, shivering and pyrexia for 
the misoprostol group compared with the placebo group. To test the diversity and heterogeneity 
of the pooled estimates, the χ2 test of heterogeneity at 5% significance level was used and the 
degree of heterogeneity was quantified on the basis of 12 test. Further meta-analysis focused on 
high quality studies by restricting the analysis to randomised controlled trials (RCTs) only. The 
GRADE system was used to classify the overall quality of evidence for each outcome33. This 
was done in two stages - for all studies and for RCTs only (by BA).  
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Results 
 
Fourteen relevant papers34-47 were identified (Figure 1). Ten of these, comprising a total of six 
studies34,39,40,43-45 (one study being reported in five papers34-38), had data on the effectiveness of 
misoprostol. There was one pilot study41, one program report42, and an evaluation of a training 
package for misoprostol administration without effectiveness data46. One study examining the 
effectiveness of community mobilisation in the uptake of misoprostol did not have a control or 
comparison group47. All four of these studies were subsequently excluded from the review.  
 
Characteristics of included studies 
Two of the six studies were double-blind randomised controlled trials (RCTs)34,43, while the 
others were contemporaneous controlled non-randomised trials39,40,44,45 (Online tables 1 and 2). 
Five studies in this review used a 600mcg dose of misoprostol, however the most recent used a 
lower dose of 400mcg45. All were conducted in a home-like setting, with five of the six studies 
focusing on home birth only39,40,43-45 and the sixth study also including ‘village sub-centres’34. In 
four of these studies the misoprostol was administered to women at birth by a frontline health 
worker (a trained Traditional Birth Attendant (TBA)40,43, Auxiliary Nurse Midwife (ANM)34 or a 
Community Health Worker (CHW)45), while in two studies it was distributed to the pregnant 
woman following counseling during antenatal care and was administered at birth either by the 
woman or her attendant39,44. All studies included some form of training for the health worker or 
education for the woman. In five of the six studies this was equally applied to both intervention 
and control arms34,39,40,43,44; however in the most recent study only the intervention group 
received education45. One RCT had a substantial program of training for TBAs in both arms of 
the study, which included the components of active management of the third stage of labour43. 
In the other three studies where misoprostol was given to the health worker training focused on 
the study protocol, identifying high risk women and danger signs34,40,45. One of these studies 
also included education for women and their families on PPH and the use of misoprostol45. In 
the two studies where only the women received the misoprostol, the education focused on birth 
preparedness, danger signs, and the correct timing and use of misoprostol39,44. 
 
Details of the person who actually administered the misoprostol were difficult to ascertain in 
most studies. Only one study reported that ‘all women received study medication per protocol’, 
in this case via the trained TBA43. In one of the studies where misoprostol was distributed 
directly to the woman, a considerable proportion of women gave birth alone or with a family 
member only (21%) suggesting that the misoprostol was essentially self-administered39. In the 
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other study the majority of women had a skilled birth attendant (54.5%) or TBA (43.9%) at the 
birth44. 
 
All studies recruited women who were planning to give birth at home; however the actual place 
of delivery was not always the home. Three studies included only women who delivered at 
home. In one study women were randomised during the third stage of labour, thus ensuring only 
home births43. In the second study, women who did not have a delivery at home were 
withdrawn39; while the most recent study randomly selected women who delivered at home from 
the delivery register45. In the remaining three studies the proportion of home births was highest 
in the two contemporaneous controlled non-randomised trials (91%44 and 79%39) and lowest in 
the RCT by Derman et al. (less than 50% in both arms)34.    
 
Details of the individual study results are available in online tables 3 and 4. The pooled results 
are shown in Figures 2 and 3, while the assessment of the quality of evidence according to 
GRADE is shown in online table 5.  
 
Effectiveness 
All six studies examined some measure of effectiveness, but there was some heterogeneity 
(online table 3). Both RCTs demonstrated a significant reduction in the incidence of postpartum 
haemorrhage (defined as blood loss >500ml) in the misoprostol group34,43. One controlled non-
randomised trial reported a reduction in PPH (blood loss >500ml)45 and another reported a 
reduction in the incidence of ‘excessive blood loss’ rather than PPH44. The pooled relative risk 
(RR) of the data from these four studies is 0.58 (95% CI: 0.38 to 0.87) (Figure 2), with a very 
low overall grade of evidence (online table 5). Restricting the analysis to only RCTs gave a 
pooled RR = 0.65 (95% CI: 0.46 to 0.91), with a high overall grade of evidence (online table 5).  
 
Three of the six studies reported a reduced need for additional uterotonics in the misoprostol 
group; pooled RR = 0.34 (95% CI: 0.16 to 0.73), with a very low overall grade of evidence 
(online table 5). Three studies reported a reduction in the need for referral for PPH; pooled RR = 
0.49 (95% CI: 0.37 to 0.66). Misoprostol also appears to confer benefit by reducing the need for 
manual removal of placenta43, blood transfusion34,40,45 and a drop in haemoglobin postpartum43 
(online table 3). None of the studies was large enough to detect a difference in maternal 
mortality. 
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Safety 
Shivering and fever were the most common side effects (online table 4). Four of the five studies 
that examined shivering reported an increase in shivering in the misoprostol group; pooled RR = 
2.18 (95% CI: 1 to 4.72) (Figure 3), with a very low overall grade of evidence (online table 5). 
The effect was more pronounced and statistically significant when only RCTs were included in 
the meta-analysis; pooled RR = 2.91 (95% CI: 2.49 to 3.4), with a moderate overall grade of 
evidence (online table 5). The association between misoprostol and pyrexia was less clear, with 
two studies suggesting an increase in pyrexia, one finding no difference between groups, and 
one suggesting a decrease (online table 4); pooled RR= 1.4 (95% CI: 0.16 to 12.09) (Figure 3), 
with a very low overall grade of evidence (online table 5). Restricting the analysis to only the 
RCTs resulted in a pooled RR= 1.64 (95% CI: 0.28 to 9.5), with a low overall grade of evidence 
(online table 5). 
 
Other adverse effects were poorly reported, or not reported at all. Only one study considered 
neonatal effects and this was reported following a post-hoc analysis35. Patted et al. examined 
neonatal vomiting, fever and diarrhea and found no difference between babies whose mothers 
took misoprostol and those that took the placebo35. None of the studies reported neonatal 
mortality. 
 
Only the two studies where misoprostol was distributed to the pregnant woman examined 
whether it was administered correctly39,44. Sanghvi et al found that all 1421 women who took 
misoprostol did so after the birth of the baby and in all 20 cases of twins the woman took the 
misoprostol after the birth of the second baby39. In the other study, qualitative data suggested 
that women took the misoprostol ‘at the correct time’44. 
 
Discussion 
Our review focuses specifically on the prevention of PPH in home birth settings, a major public 
health challenge in LRCs. Previous reviews that have considered the effectiveness of 
misoprostol27,31 have not discriminated by setting (including both facility and community settings) 
and included routes of administration that could be argued to be difficult for women or untrained 
attendants to correctly administer. We found quality evidence that administration of oral 
misoprostol through frontline health workers in home birth settings in LRCs is associated with a 
significant reduction in the incidence of PPH. These frontline workers included auxiliary 
midwives (classified by WHO as midwifery personnel), and trained TBAS and CHWs (classified 
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by WHO as community/traditional health workers48). The association seems to be maintained 
when misoprostol is distributed directly to women, rather than through a health worker, and 
administered either by the woman or her attendant; however the quality of this evidence is very 
low. In all studies in this review misoprostol was distributed as part of a package of care that 
included training of birth attendants and/or education of women. This is an important 
consideration if misoprostol is to be considered for inclusion in clean birth kits (CBKs). Previous 
research suggests that CBKs are also typically distributed as part of a broader package of care 
that includes training and/or education49, and therefore extending this to include information 
about misoprostol administration may be feasible. 
 
The quality evidence regarding the incidence of PPH might appear to warrant a “strong” 
recommendation for the use of misoprostol, particularly when the evidence from RCTs alone is 
considered33. However, the GRADE system also includes consideration of undesirable effects. 
Our review clarifies the positive association between oral misoprostol use and shivering, 
however the association with pyrexia remains unclear. It is likely that this uncertainty is due to 
measurement issues, as in all studies side effects were based on women’s reports. Mobeen et 
al. note that they did not attempt to systematically measure body temperature as an indicator of 
pyrexia, and that low rates of adverse effects could be a result of recall bias43. Previous 
research examining oral and sublingual misoprostol administration in facility settings found a 
significant increase in pyrexia, and this was greater where the dose was 600mcg compared to 
400mcg29. Although expert groups have recommended 600mcg as the oral dose of misoprostol 
for PPH prevention where other treatments are unavailable, they acknowledge the limited 
evidence base for this recommendation15,31. Our findings do not clarify the picture. Most of the 
studies in this review used the higher dose of misoprostol and the one study that examined the 
use of a lower dose in the home setting did not collect data on side effects in the control arm 
(personal communication)45. In addition, the inclusion of ‘intensive maternity services’ in the 
intervention arm of this study could have explained the reduced incidence of PPH45. Further 
research is needed to examine the effectiveness of using a lower dose in a home setting. Other 
adverse effects have not been systematically captured in studies; the only study to explicitly 
examine neonatal outcomes found no differences in the incidence of neonatal fever, vomiting 
and diarrhea on the first postpartum day35. 
 
We found limited information in the studies in our review to address concerns about the 
potential for inappropriate or inadvertent use. Hofmeyer and Gulmezoglu noted the potential for 
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misoprostol to be used to augment labour, or to be taken in error, particularly in the case of 
twins50. In our review, only three studies examined the timing of administration and they found 
no cases of error39,44,45. Indeed Sanghvi et al. report that 96% of women took the misoprostol 
immediately after delivery of the baby and before the placenta was delivered39. In the study by 
Nasreen et al. 92% of women received the misoprostol from CHWs within 30 minutes of birth45. 
However, all three studies included substantial programmes of education and the two studies 
that distributed misoprostol to women only did so to those women who were able to 
‘demonstrate understanding’ of correct and safe use39,44. The three studies that examined 
misoprostol administration by trained attendants did not report details on safe administration. 
However, personal communication with the author of the most recent RCT confirmed that all 
trained TBAs followed the study protocol and that there were no errors43. A program report from 
Bangladesh suggests that timing may be an issue, with “a considerable delay in taking the 
tablets after delivery observed in several cases” and a number of women who forgot to take 
them41. The findings from the recent community mobilisation in Nigeria also raise concerns47. 
Despite a significant programme of educational interventions, the study found that 18% of 
women did not get or did not take misoprostol. Of those women who did take the misoprostol, 
12% took the dose at the wrong time and 2% took the wrong dose47. A symposium held in 
January of this year by USAID indicated that a number of countries are rolling out programs of 
community-based misoprostol administration and it is hoped that these will add to knowledge on 
safe administration. Early data from a pilot project in Nepal suggests that 93% of women report 
taking misoprostol after the birth of the baby but before the delivery of the placenta, with the 
remaining 7% taking after both baby and placenta have been delivered51. In Senegal, no 
administration errors were detected following the introduction of misoprostol at community 
level46. This was achieved through a 6 day training program for auxiliary midwives and 
supervisors on misoprostol administration, and strict controls on storage and distribution of the 
tablets. Further research is needed to examine compliance by both trained birth attendants and 
women. 
 
None of the six studies indicated that the misoprostol tablets were used for anything other than 
the prevention of PPH. However, further research is needed to assess the impact of misoprostol 
distribution outside of the tight controls of clinical trials. The impact that distributing misoprostol 
might have on perceptions regarding the need for skilled care also needs to be examined. Less 
than half of the women who received education about PPH as part of a recent programme of 
community-based distribution of misoprostol acknowledged the need for referral in the event of 
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PPH47. It was suggested that more needed to be done to get the educational message through, 
however the potential for community based interventions to act as a disincentive to facility care 
also needs to be examined.  
 
Our review is limited by our focus on English language papers and relevant studies published in 
other languages could have been missed. However, we found no non-English language 
abstracts and no additional non-English language studies were recommended by experts in the 
field. We excluded studies where misoprostol tablets were administered sublingually, since this 
route has been associated with a higher rate of maternal fever than the oral route28 and could 
require more training in administration, thus making it less amenable for home use. Although 
this could be considered a limitation, in fact most studies using sublingual misoprostol were 
conducted within a facility setting and so would have been excluded from our review for this 
reason. All studies in the review had some elements of measurement bias with respect to the 
side effects because they relied upon women’s recall of shivering and pyrexia. This may have 
led to an underestimation of the side effects. Although the non-randomised studies also had 
issues with regard to measurement of PPH, the two randomised controlled trials used the most 
stringent measurement methods possible given the community setting. There were similar 
issues in the non-randomised studies with regard to the administration of misoprostol and this 
might be a cause of bias. However, there was no potential for drug administration bias in the 
RCTs as both had very clear protocols. Both RCTs noted temporal trends with a reduction in 
PPH occurring in both the intervention and the control group as the trials progressed34,43. The 
authors surmised that other factors such as a raised awareness of PPH or a training effect could 
have contributed to the reduction in the placebo group. A significantly greater reduction in the 
incidence of PPH was seen in the intervention arms in both trials, suggesting an association 
with misoprostol use. However, further high quality randomised control trials are required to 
confirm the association, particularly in different implementation settings. Caution must also be 
exercised in generalising beyond low risk women, since both RCTs excluded women with a 
history of high risk conditions.  
 
Conclusion  
There is quality evidence that distribution of oral misoprostol through frontline health workers in 
home birth settings in LRCs is associated with a significant reduction in the incidence of PPH, 
as well as in the need for additional uterotonics and for referral. This association seems to be 
maintained when misoprostol is distributed directly to women, rather than through a health 
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worker, and administered either by the woman or her attendant; however the quality of this 
evidence is very low. Adverse effects have not been systematically captured, and there has 
been limited consideration of the potential for inappropriate or inadvertent use of misoprostol. 
The finding that distribution of oral misoprostol through frontline health workers is effective in 
reducing the incidence of PPH may be a significant step forward in reducing maternal deaths in 
low resource countries. Further evidence is needed to inform the development of 
implementation and safety guidelines on the routine availability of misoprostol in different home 
birth settings.  
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Figure 2. Pooled relative risk for key variables on effectiveness 
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Figure 3. Pooled relative risk for key variables on safety 
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Additional online table 1. Studies examining the effects of oral misoprostol   
 
 
Source Location of study Participants Intervention Control Primary outcome 
measures 
Contemporaneous Controlled Randomised Trials   
Mobeen et al., 
2010 
 
Remote villages of Chitral, 
Khyber Pakhtunkwa 
Province, Pakistan  
Planned home births  
1119 women without 
pregnancy complications 
(I=534, C=585)  
600 mcg oral misoprostol 
administered by trained 
TBAs. Training on AMTSL 
 
Placebo 
Training for TBAs on 
AMTSL 
Blood loss > 500ml 
Drop in haemoglobin > 
2g/dl 
 
Derman et al., 
2006 
Rural Belgaum District,  
Karnataka State, India  
Home-birth settings (home 
& village sub centres) 
1620 low-risk women  
(I =812, C=808)  
 
600 mcg oral misoprostol 
administered by ANMs 
Training for ANMs on study 
protocol, identifying high risk 
women and danger signs 
Placebo 
Training for ANMs on 
study protocol, identifying 
high risk women and 
danger signs 
Blood loss > 500ml 
 
Contemporaneous Controlled Non-Randomised Trials   
Nasreen et 
al., 2011 
Rural Nilphamari and 
Naogaon districts in 
Bangladesh. 
Home births 
2017 women (I = 1009 – 
884 received misoprostol, 
C=1008) 
Education by CHW, intensive 
maternity care + 400mcg 
oral misoprostol 
administered by CHWs. 
Essential health care Blood loss > 500ml 
 
Sanghvi et al., 
2010 
6 rural districts chosen 
from Faryab, Jawzjan & 
Kabul provinces, 
Afghanistan. 
Home births 
3187 women 
(I=2039  - 1421 took 
misoprostol, C=1148) 
 
Education by CHW + 600 
mcg oral misoprostol + 
pictorial messages given to 
women 
Education by CHW Misoprostal use; 
Reported symptoms; 
Adverse effects; 
Acceptability; Feasibility 
– willingness & 
motivation 
Prata et al., 
2009 
Rural Tigray, Ethiopia  
Home births 
1000 women  - assisted 
deliveries were then 
excluded 966 women 
(I=485, C=481)   
 
600 mcg oral misoprostol 
administered by trained 
TBAs 
Training on study protocol 
Current practice 
Training on study 
protocol 
Reported symptoms; 
Referrals; Additional 
interventions 
 
Sanghvi et al., 
2004 
Rural Bandung and 
Subang districts, 
Indonesia. 
Home births 
1855 women 
(I=1360 – 999 took 
misoprostol, C=495)  
 
Education by CHW + 600 
mcg oral misoprostol + 
pictorial messages given to 
women 
Education by CHW Acceptability & uptake; 
Excessive blood loss; 
Emergency referral; 
Adverse effects 
 
21 
 
Additional online table 2. Critical appraisal of studies  
 
Source Study 
design
b
 
Sample Control group Measurements and 
outcomes 
Completeness Distorting influences 
Contemporaneous Controlled Randomised Trials    
Mobeen 
et al., 
2010 
 
++ Included only women 
‘in general good health’ 
and planning to give 
birth at home. 
 
Random allocation –  
computer generated 
random code in blocks - 
independently 
implemented 
Double blind – placebo. PPH 
collected using a drape and 
weighed (early challenges 
were considered pilot 
phase).  Indirect 
measurement (self-report) of 
pyrexia & shivering 
Loss to follow-up = 1 
intervention, 2 control. Missing 
blood loss data = 19 
intervention, 25 control.  
Intention-to-treat analyses. 
All data collected in first 7 
months excluded due to 
measurement issues. 
Temporal trends - other 
factors (e.g. training) may 
have contributed to PPH 
reduction. 
Derman 
et al., 
2006 
++ Excluded women with 
pregnancy 
complications or history 
of high risk conditions 
 
Random allocation - 
computer-generated 
 list - independently 
implemented 
Double blind – placebo. PPH 
measured using a calibrated 
collection drape. Indirect 
measurement (self-report) of 
pyrexia & shivering 
No loss to follow-up reported.  
Intention-to-treat analyses. 
Temporal trend - declining 
PPH also noted in placebo 
group. 
Contemporaneous Controlled Non-Randomised Trials    
Nasreen 
et al., 
2011 
- Randomly selected 
from birth register in 
one district. 
Control - non-users in 
second district. No 
randomisation and no 
blinding. 
Self reported measurement 
of PPH, pyrexia & shivering. 
Analysis based on 87% of 
intervention group who received 
misoprostol. 
Lack of adequate control 
over confounding factors 
(education, & financial 
state). Intervention 
included intensive service 
Sanghvi 
et al., 
2010 
+ All pregnant women in 
one district. 
 
Control - non-users in 
second district. No 
randomisation & no 
blinding. 
Self reported measurement 
of PPH (2 soaked cloths), 
pyrexia & shivering. 
18 women in intervention not 
offered misoprostol. No loss to 
follow-up reported for main 
outcomes, but 3 women not 
available for follow-up interview.   
Lack of adequate control 
over confounding factors. 
Prata et 
al., 2009 
+ Pregnant women in 
selected villages - 
limited information on 
selection criteria. 
 
Control - non-users in 
selected villages. No 
randomisation & no 
blinding.  
Visual inspection method to 
assess PPH. Self reported 
measurement of pyrexia & 
shivering. 
34 women withdrawn (15 
intervention, 19 control) because 
did not have vaginal birth at 
home. 5 maternal deaths (1 
intervention, 4 control). 
Lack of adequate control 
over confounding factors 
(reproductive history of 
PPH & education). 
Sanghvi 
et al., 
2004 
+ All pregnant women in 
one district. 
Control - non-users in 
‘comparable’ second 
district. No 
randomisation & no 
blinding. 
Self reported measurement 
of PPH, pyrexia & shivering. 
41 women lost to follow up – 
moved or pregnancy loss (36 
intervention, 5 control). Three 
maternal deaths (2 intervention, 
1 control). 
Lack of adequate control 
over confounding factors 
(education, parity & 
reproductive history of 
PPH). 
                                                 
b
 Adapted from the SIGN levels of evidence. Key:  ++ (High level of confidence the analysis is assessing a causal association e.g. good analysis of cluster-randomised trial)  + (Moderate 
level of confidence the analysis is assessing a causal association e.g. poor cluster-randomised trial; non-randomised cluster-controlled trial without obvious important confounding; before-
after study of comparable groups, with no reason to suspect important time trends; possibly 'causal' analyses of cross-sectional data e.g. propensity scores / instrumental variable) _ (Low 
level of confidence the analysis is assessing a causal association e.g.  Cross-sectional user / non-user comparisons, with adjustment for socio-economic and relevant behavioural 
differences.)  _ _ (Very Low level of confidence the analysis is assessing a causal association e.g. cross-sectional user / non-user comparisons without adequate adjustment, or where large 
differences require large adjustments.) 
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Additional online table 3. Blood loss and associated sequelae 
 
Source 
 
Intervention Control Effect size  
RR (95% CI) 
Significance  
     
Incidence of PPH >500ml     
Mobeen et al. 2010 85/514 122/558 0.76 (0.59, 0.97) 0.03 
Derman et al. 2006 52/812 97/808 0.53 (0.39, 0.74) < 0.001 
Nasreen et al. 2011 14/884 65/1008 0.25 (0.14, 0.43) < 0.001 
     
‘Excessive blood loss’     
Sanghvi, et al.  2004   117/999 66/489 0.87 (0.65, 1.15) 0.32 
     
Use of additional uterotonics     
Derman et al. 2006 3/812 6/808 0.50 (0.12, 1.98) 0.32 
Nasreen et al. 2011 3/884 26/1008 0.13 (0.04, 0.43) < 0.001 
Sanghvi et. al. 2010 54/1420    
Prata et al. 2009 42/485 91/481 0.46 (0.32, 0.65) < 0.001 
     
Use of any uterotonic     
Sanghvi et. al. 2010 1960/2039 295/1148 3.74 (3.39, 4.13) < 0.001 
     
Need for referral for PPH     
Mobeen et al. 2010 2/533 3/583 0.73 (0.12, 4.35) 0.73 
Prata et al. 2009  43/485 91/481 0.47 (0.33, 0.66) < 0.001 
Sanghvi, et al. 2004   28/1322 19/489 0.55 (0.31, 0.97) 0.04 
     
Interval between delivery of baby & placenta (>30 min)   
Nasreen et al. 2011 31/884 52/1008 0.68 (0.44, 1.05) 0.08 
     
Manual removal of placenta     
Nasreen et al. 2011 26/884 68/1008 0.44 (0.28, 0.68) < 0.001 
     
Blood transfusion     
Derman et al. 2006 1/812 7/808 0.14 (0.02, 1.15) 0.07 
Nasreen et al. 2011 0/884 2/1008 -  
Prata et al. 2009 4/485 30/481 0.13 (0.05, 0.37) < 0.001 
     
Drop in Hb > 3g/dl     
Mobeen et al. 2010 27/528 55/572 0.53 (0.34, 0.83) < 0.01 
     
Maternal death     
Mobeen et al. 2010 0/534 0/585 -  
Derman et al. 2006 0/812 1/678 -  
Sanghvi  et. al. 2010 1/2039 0/1148 -  
Prata et al. 2009 1/500 4/500 -  
Sanghvi, et al. 2004   2/1360 1/495 -  
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Additional online table 4. Adverse effects 
 
Source 
 
Intervention Control Effect size  
RR (95% CI) 
Significance  
     
Shivering     
Mobeen et al. 2010 50/533 23/583 2.38 (1.47, 3.84) < 0.001 
Derman et al. 2006 419/812 140/808 2.98 (2.53, 3.51) < 0.001 
Sanghvi et. al. 2010 575/2039 381/1148 0.85 (0.76, 0.95) < 0.01 
Prata et al. 2009 59/485 32/481 1.83 (1.21, 2.76) < 0.01 
Sanghvi, et al.  2004   442/999 48/489 4.51 (3.42, 5.95) < 0.001 
     
Pyrexia (≥38°C)     
Mobeen et al. 2010 4/533 7/583 0.63 (0.18, 2.12)    0.45 
Derman et al. 2006 34/812 9/808 3.76 (1.81, 7.79) < 0.001 
Sanghvi et. al. 2010 173/2039 374/1148 0.26 (0.22, 0.31) < 0.001 
Sanghvi, et al.  2004   352/999 28/489 6.15 (4.25, 8.90) < 0.001 
     
Need for referral for any complication    
Mobeen et al. 2010 18/533 20/583 0.98 (0.53, 1.84) 0.96 
Derman et al. 2006 4/812 12/808 0.33 (0.11, 1.02) 0.06 
Nasreen et al. 2011 3/884 11/1008 0.31 (0.09, 1.11) 0.07 
Sanghvi, et al.  2004   114/1322 62/489 0.68 (0.51, 0.91)    < 0.01 
.     
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Additional online table 5. GRADE classification of the overall quality of evidence for each outcome 
All studies  RCTs only 
Outcomes Anticipated absolute effects  Relative 
effect 
(95% CI) 
No of 
Participants 
(studies) 
Quality of the 
evidence 
(GRADE) 
Outcomes Anticipated absolute effects  Relative 
effect 
(95% CI) 
No of 
Participants 
(studies) 
Quality of the 
evidence 
(GRADE) 
Risk with 
control 
Risk difference with blood 
loss & associated 
sequelae (95% CI) 
Risk with 
control 
Risk difference with blood 
loss & associated 
sequelae (95% CI) 
    
    
PPH-1 Study population RR 0.58  
(0.38 to 0.87) 
6072 
(4 studies) 
⊕⊝⊝⊝ 
very low
1,2  
due 
to risk of bias, 
indirectness 
PPH-2 Study population RR 0.65  
(0.46 to 0.91) 
2692 
(2 studies) 
⊕⊕⊕⊕ 
high 122 per 
1000 
51 fewer per 1000 
(from 16 fewer to 76 fewer) 
160 per 
1000 
56 fewer per 1000 
(from 14 fewer to 87 fewer) 
Moderate Moderate 
128 per 
1000 
54 fewer per 1000 
(from 17 fewer to 79 fewer) 
169 per 
1000 
59 fewer per 1000 
(from 15 fewer to 91 fewer) 
Use of 
additional 
uterotonics 
Study population RR 0.34  
(0.16 to 0.73) 
4478 
(3 studies) 
⊕⊝⊝⊝ 
very low
2,3 
due 
to risk of bias, 
inconsistency, 
indirectness, 
imprecision
 
     
54 per 
1000 
35 fewer per 1000 
(from 14 fewer to 45 fewer) 
Moderate 
26 per 
1000 
17 fewer per 1000 
(from 7 fewer to 22 fewer) 
shivering-1 Study population RR 2.18  
(1 to 4.72) 
8377 
(5 studies) 
⊕⊝⊝⊝ 
very low
1,3,4,5,6  
due to risk of 
bias, 
inconsistency, 
indirectness, 
large effect 
shivering-2 Study population RR 2.91  
(2.49 to 3.4) 
2736 
(2 studies) 
⊕⊕⊕⊝ 
moderate
5,6 
due to 
imprecision 
178 per 
1000 
210 more per 1000 
(from 0 more to 662 more) 
117 per 
1000 
224 more per 1000 
(from 175 more to 281 more) 
Moderate Moderate 
98 per 
1000 
116 more per 1000 
(from 0 more to 365 more) 
106 per 
1000 
202 more per 1000 
(from 158 more to 254 more) 
pyrexia-1 Study population RR 1.4 
(0.16 to 12.09) 
7411 
(4 studies) 
⊕⊝⊝⊝ 
very low
1,3,5,6
   
due to risk of 
bias, 
indirectness, 
large effect 
pyrexia-2 Study population RR 1.64  
(0.28 to 9.5) 
2736 
(2 studies) 
⊕⊕⊝⊝ 
low
5,6
  due to 
indirectness, 
imprecision 
138 per 
1000 
55 more per 1000 
(from 116 fewer to 1000 more) 
12 per 
1000 
7 more per 1000 
(from 8 fewer to 98 more) 
Moderate Moderate 
35 per 
1000 
14 more per 1000 
(from 29 fewer to 388 more) 
12 per 
1000 
8 more per 1000 
(from 9 fewer to 102 more) 
*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention 
(and its 95% CI).  CI: Confidence interval; RR: Risk ratio;  
GRADE Working Group grades of evidence:   High quality: Further research is very unlikely to change our confidence in the estimate of effect.   Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and 
may change the estimate.   Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.   Very low quality: We are very uncertain about the estimate. 
1. Sanghvi et al, 2004 (NON-RCT): No randomisation, no blinding, lack of adequate control over confounding (education, parity, etc.). Asian (primarily rural) population. Self reported measurement of PPH, pyrexia and shivering. Self-administration of misoprostol, and 
non-user (non-placebo) as control group.     
2. Nasreen et al, 2011 (NON-RCT): No randomisation, no blinding, lack of adequate control over confounding (education, financial status, etc.). Asian (primarily rural) population. Self reported measurement of PPH, pyrexia and shivering. Non-user (non-placebo) as 
control group. 
3. Sanghvi et al, 2010 (NON-RCT): No randomisation, no blinding, lack of adequate control over confounding. Asian rural population. Self reported measurement of PPH, pyrexia and shivering. Self-administration of misoprostol, and non-user (non-placebo) as control 
group. 
4. Prata et al, 2009 (NON-RCT): No randomisation, no blinding, lack of adequate control over confounding (age, education, etc.). African rural population. Visual inspection method to assess PPH. Self reported measurement of pyrexia and shivering. Non-user (non-
placebo) as control group. 
5. Darmen et al, 2006 (RCT): Asian rural population. Indirect measurement (self-report) of pyrexia and shivering. 
6. Mobeen et al, 2010 (RCT): Asian rural population. Indirect measurement (self-report) of pyrexia and shivering. 
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